Anti-Human SOST/Sclerostin Reference Antibody (Romosozumab, RUO)

Description: Romosozumab (BS10640) is a research-grade recombinant antibody targeting SOST. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG2-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 2mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: SOST,Sclerostin
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: 785A070802,AMG785,CDP-7851,romosozumab-aqqg,sclerostinAb,CAS:909395-70-6
Background: Sclerostin (SOST) is a ~24 kDa protein. Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
Note: For research use only. Not suitable for clinical or therapeutic use.